Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI).

Full DD Report for SPPI

You must become a subscriber to view this report.


Recent News from (NASDAQ: SPPI)

Week In Review: China Pharmas Announce Deals Worth $1.5 Billion
Deals and Financings WuXi AppTec (SHA: 603259), China's largest CRO/CMO, completed a $1 billion IPO on the Hong Kong markets, pricing the offering in the middle of the expected range. In May, WuXi became a public company by completing a $328 million IPO in Shanghai. Since the offering, the...
Source: SeekingAlpha
Date: December, 10 2018 00:48
Spectrum Pharmaceuticals Announces Positive Results from Phase 2 Trial Evaluating Use of Oral Leucovorin to Potentially Mitigate Mucositis in Patients Treated with FOLOTYN® (pralatrexate)
In practice, FOLOTYN use has caused Grade 2 or higher oral mucositis in more than half of patients, potentially impacting treatment of relapsed or refractory Peripheral T-cell Lymphoma (PTCL) This was the first prospective study to evaluate the effect of oral leucovorin in preventing o...
Source: Business Wire
Date: December, 03 2018 07:00
Notable earnings after Thursday's close
AGO , AL , ALTR , AMBR , AMC , AMPH , AQN , ARRS , ASRT , ATVI , BOJA , BPI , BRS , BW , CBPX , COLD , COLL , CTL , CYRX , DBX , DIS , DOX , ECOM , EGAN , EPAY , ERI , FGEN , FOE , FSCT , FSM , FTCH , GMED , HDP , HTZ , ICUI , JAG , JJSF , LGF.A , LOPE...
Source: SeekingAlpha
Date: November, 07 2018 17:35
Spectrum Pharmaceuticals to Present Corporate Update at the Jefferies 2018 London Healthcare Conference on November 14
Spectrum Pharmaceuticals (NasdaqGS: SPPI) , a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the company's business strategy and commercial and development-stage prog...
Source: Business Wire
Date: November, 07 2018 07:00
Spectrum Pharmaceuticals Announces Third Quarter 2018 Financial Results Teleconference and Webcast
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced it will host a teleconference and webcast with management to discuss the third quarter 2018 fin...
Source: Business Wire
Date: November, 01 2018 07:00
Spectrum Pharmaceuticals to Present Corporate Update at the 2018 Cantor Global Healthcare Conference on October 2
Spectrum Pharmaceuticals (NasdaqGS: SPPI) , a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the company's business strategy and commercial and development-stage prog...
Source: Business Wire
Date: September, 27 2018 07:00
Spectrum Pharma adds first-line patients to mid-stage study of poziotinib in NSCLC
Spectrum Pharmaceuticals (NASDAQ: SPPI ) has added two new cohorts to its Phase 2 clinical trial, ZENITH20, assessing pan-HER inhibitor poziotinib in patients with non-small cell lung cancer (NSCLC). More news on: Spectrum Pharmaceuticals, Inc., Healthcare stocks news, Read more ... ...
Source: SeekingAlpha
Date: September, 12 2018 08:42
Spectrum Pharmaceuticals Expands Poziotinib Clinical Trial Into First-Line Therapy and Doses First Patient
Spectrum’s Phase 2 non-small cell lung cancer (NSCLC) study expanded to include two new cohorts for first-line NSCLC patients with EGFR or HER2 exon 20 insertion mutations Phase 2 study now includes four cohorts with each cohort being an independent study with pre-specified stat...
Source: Business Wire
Date: September, 12 2018 07:00
Your Daily Pharma Scoop: Spectrum Positive, Xenon Expands, ViiV's Label Receives FDA Clearance
Stocks in News: SPPI, XENE Spectrum Pharma's poziotinib continues to show positive action Discussion : Spectrum Pharmaceuticals ( SPPI ) reported its plan to present updated data from a Phase 2 clinical trial of poziotinib in EGFR exon 20-mutant non-small cell lung cancer (N...
Source: SeekingAlpha
Date: September, 10 2018 00:02
Premarket Gainers as of 9:05 am (09/06/2018)
ARWR +31%  on positive analyst action . More news on: Arrowhead Pharmaceuticals, New Age Beverages Corporation, Naked Brand Group Limited, Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: September, 06 2018 09:26

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-1411.4711.6111.8711.37638,938
2018-12-1312.7011.6012.7711.38931,383
2018-12-1212.9612.698413.2012.60828,844
2018-12-1112.8912.8313.0912.70362,648
2018-12-1012.3012.7012.8012.10541,509

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1465,127247,99426.2615Cover
2018-12-13120,198387,52931.0165Cover
2018-12-1264,346154,64641.6086Short
2018-12-1129,58883,78035.3163Short
2018-12-1082,165180,94245.4096Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on SPPI.


About Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI)

Logo for Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI)

Not available

 

Contact Information

 

 

Current Management

  • Rajesh C. Shrotriya / President, CEO

Current Share Structure

  • Market Cap: $2,096,710,305 - 05/18/2018
  • Issue and Outstanding: 104,055,102 - 04/30/2018

 


Recent Filings from (NASDAQ: SPPI)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: August, 09 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: August, 09 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: August, 08 2018
Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: July, 31 2018
An annual report of employee stock purchase savings and similar plans
Filing Type: 11-KFiling Source: edgar
Filing Date: June, 26 2018
Post-effective amendment to an S-8 filing
Filing Type: S-8 POSFiling Source: edgar
Filing Date: June, 18 2018
Post-effective amendment to an S-8 filing
Filing Type: S-8 POSFiling Source: edgar
Filing Date: June, 18 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: June, 18 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: June, 18 2018
Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: May, 14 2018

 

 


Daily Technical Chart for (NASDAQ: SPPI)

Daily Technical Chart for (NASDAQ: SPPI)


Stay tuned for daily updates and more on (NASDAQ: SPPI)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: SPPI)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in SPPI is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of SPPI and does not buy, sell, or trade any shares of SPPI. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/